glp 1 pancreatic cancer risk Semaglutide: What we know about safety and Frontiers | Reassessing cancer risk

Now that millions of people are taking these medications far beyond the scope of clinical trials researchers are beginning to understand why

Based on analysis of The Food and Drug Administrations (FDA) Adverse Effect Reporting System (FAERS), adverse effects of GLP-1 RA-related medications including semaglutide, exenatide, liraglutide, dulaglutide, and tirzepatide were analyzed represent 47 cumulative years of observation across all drugs included in the analysis [11]

Chen, H

This delayed stomach emptying contributes to feelings of fullness and reduced appetite, which supports therapeutic goals

A case report highlighted a patient on semaglutide exhibiting significant gastric content despite fasting, indicating the need for caution during anesthesia

Brief exposure (under 30 minutes) to moderate heat typically does not significantly damage the medication